WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 67% more annual revenue ($59.32B vs $35.48B). MDT leads profitability with a 13.0% profit margin vs 11.5%. MDT appears more attractively valued with a PEG of 1.50. BUD earns a higher WallStSmart Score of 61/100 (C+).

BUD

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 10.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDUndervalued (+51.3%)

Margin of Safety

+51.3%

Fair Value

$158.65

Current Price

$68.06

$90.59 discount

UndervaluedFair: $158.65Overvalued
MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD5 strengths · Avg: 8.6/10
EPS GrowthGrowth
63.3%10/10

Earnings expanding 63.3% YoY

Market CapQuality
$133.23B9/10

Large-cap with strong market position

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.9%8/10

Strong operational efficiency at 24.9%

Free Cash FlowQuality
$9.89B8/10

Generating 9.9B in free cash flow

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

BUD2 concerns · Avg: 4.0/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Revenue Growth.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

BUD carries more volatility with a beta of 0.73 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

BUD generates stronger free cash flow (9.9B), providing more financial flexibility.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BUD scores higher overall (61/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?